Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals

Diabetes Care

Volumn 32, Issue 3, 2009, Pages 474-480

  Worm, Signe W ^a   Sabin, Caroline A ^b   Reiss, Peter ^c   El Sadr, Wafaa ^d   Monforte, Antonella D'Arminio ^e   Pradier, Christian ^f   Thiebaut, Rodolphe ^g   Law, Matthew ^h   Rickenbach, Martin ⁱ   De Wit, Stephane ^j   Lundgren, Jens D ^a   Friis Møller, Nina ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d HARLEM HOSPITAL CENTER   (United States)

^e UNIVERSITY OF MILAN   (Italy)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^g UNIVERSITÉ DE BORDEAUX   (France)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^j SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PROSPECTIVE STUDY; RISK REDUCTION;

ADULT; ANTI-HIV AGENTS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; FEMALE; HIV INFECTIONS; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 64749106543     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-1394     Document Type: Article

References (25)

1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12:F51-F58, 1998
2. De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, El-Sadr W, Monforte A, Fontas E, Law MG, Friis-Moller N, Phillips A: Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 31:1224-1229, 2008
3. Jerico C, Knobel H, Montero M, Ordonez-Llanos J, Guelar A, Gimeno JL, Saballs P, Lopez-Colomes JL, Pedro-Botet J: Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 28:132-137, 2005
4. Jacobson DL, Tang AM, Spiegelman D, Thomas AM, Skinner S, Gorbach SL, Wanke C: Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr 43:458-466, 2006
5. Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, Powderly W, Yarasheski K: Metabolic syndrome in HIV-infected patients from an urban, midwestern US out- patient population. Clin Infect Dis 44: 726-734, 2007
6. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A: Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 30:113-119, 2007
7. Lewden D, Tay M, Rosenthal E, Burty E, Bonnet F, Burty C, Costagliola D: Causes of death among HIV-infected adults in France in 2005 and evolution since 2000. In Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007, Poster 976
8. Expert Panel on Detection, Evaluation and Treatment on High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Educational Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
9. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP: National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 110:1251-1257, 2004
10. Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ: Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 112:666-673, 2005
11. Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28:2289-2304, 2005
12. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, Thiebaut R, De WS, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD: Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356:1723-1735, 2007
13. Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Circulation 106:3143-3421. 2002
14. Friis-Moller N, Sabin CA, Weber R, d'Arminio MA, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De WS, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD: Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349:1993-2003, 2003
15. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfar- lane PW, Packard CJ, Cobbe SM, Shepherd J: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108:414-419, 2003
16. Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L: Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 332:878-882, 2006
17. Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ, Ford I, Forouhi NG, Freeman DJ, Jukema JW, Lennon L, Macfarlane PW, Murphy MB, Packard CJ, Stott DJ, Westendorp RG, Whincup PH, Shepherd J, Wannamethee SG: Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 371:1927-1935, 2008
18. Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, Cooper DA, Emery S: Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 21:2445-2453, 2007
19. Glass TR, Ungsedhapand C, Wolbers M, Weber R, Vernazza PL, Rickenbach M, Furrer H, Bernasconi E, Cavassini M, Hirschel B, Battegay M, Bucher HC: Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med 7:404-410, 2006
20. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De WS, Law M, d'Arminio MA, Friis-Moller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371:1417-1426, 2008
21. Lundgren JD, Neuhaus J, Babiker A, Cooper D, Duprez D, El-Sadr. W, Emery S, Gordin F, Kowalska J, Phillips A, Prineas RJ, Reiss P, Sabin CA, Tracy RP, Weber R, Grund B, Neaton, J D.: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 22:F17-F24, 2008
22. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, Wensley F, Higgins JP, Lennon L, Eiriksdottir G, Rumley A, Whincup PH, Lowe GD, Gudnason V: Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLo S Med 5:e78, 2008
23. Gale EA: Should we dump the metabolic syndrome? Yes. BMJ 336:640, 2008
24. Alberti KG, Zimmet PZ: Should we dump the metabolic syndrome? No. BMJ 336: 641, 2008
25. Lundgren JD, Battegay M, Behrens G, De WS, Guaraldi G, Katlama C, Martinez E, Nair D, Powderly WG, Reiss P, Sutinen J, Vigano A: European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 9:72-81, 2008